David J. Hunter, M.B., B.S., Sc.D.
doi : 10.1056/nejmp2102550
N Engl J Med 2021; 385:481-484
James O’Connell, M.B., B.Ch., B.A.O., and Derek T. O’Keeffe, M.B., B.Ch., M.D., Ph.D.
doi : 10.1056/nejmp2102256
N Engl J Med 2021; 385:484-487
Monica B. Vela, M.D., Marshall H. Chin, M.D., M.P.H., and Monica E. Peek, M.D., M.P.H.
doi : 10.1056/nejmp2105270
N Engl J Med 2021; 385:487-489
Leonore A. Dluhy, B.A., Brendan Abel, J.D., and Robert G. Dluhy, M.D.
doi : 10.1056/nejmp2104468
N Engl J Med 2021; 385:490-491
Julian D. Gillmore, M.D., Ph.D., Ed Gane, M.B., Ch.B., Jorg Taubel, M.D., Justin Kao, M.B., Ch.B., Marianna Fontana, M.D., Ph.D., Michael L. Maitland, M.D., Ph.D., Jessica Seitzer, B.S., Daniel O’Connell, Ph.D., Kathryn R. Walsh, Ph.D., Kristy Wood, Ph.D., Jonathan Phillips, Ph.D., Yuanxin Xu, M.D., Ph.D., Adam Amaral, B.A., Adam P. Boyd, Ph.D., Jeffrey E. Cehelsky, M.B.A., Mark D. McKee, M.D., Andrew Schiermeier, Ph.D., Olivier Harari, M.B., B.Chir., Ph.D., Andrew Murphy, Ph.D., Christos A. Kyratsous, Ph.D., Brian Zambrowicz, Ph.D., Randy Soltys, Ph.D., David E. Gutstein, M.D., John Leonard, M.D., Laura Sepp-Lorenzino, Ph.D., and David Lebwohl, M.D.
doi : 10.1056/nejmoa2107454
N Engl J Med 2021; 385:493-502
Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein in tissues, predominantly the nerves and heart. NTLA-2001 is an in vivo gene-editing therapeutic agent that is designed to treat ATTR amyloidosis by reducing the concentration of TTR in serum. It is based on the clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR-Cas9) system and comprises a lipid nanoparticle encapsulating messenger RNA for Cas9 protein and a single guide RNA targeting TTR.
Juan P. Fr?as, M.D., Melanie J. Davies, M.D., Julio Rosenstock, M.D., Federico C. Pérez Manghi, M.D., Laura Fern?ndez Land?, M.D., Brandon K. Bergman, Pharm.D., Bing Liu, Ph.D., Xuewei Cui, Ph.D., and Katelyn Brown, Pharm.D. for the SURPASS-2 Investigators*
doi : 10.1056/nejmoa2107519
N Engl J Med 2021; 385:503-515
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.
Rebecca Mathew, M.D., Pietro Di Santo, M.D., Richard G. Jung, Ph.D., Jeffrey A. Marbach, M.B., B.S., Jordan Hutson, M.D., Trevor Simard, M.D., F. Daniel Ramirez, M.D., David T. Harnett, M.D., Anas Merdad, M.B., B.S., Aws Almufleh, M.B., B.S., Willy Weng, M.D., Omar Abdel-Razek, M.D., Shannon M. Fernando, M.D., Kwadwo Kyeremanteng, M.D., M.H.A., Jordan Bernick, M.Sc., George A. Wells, Ph.D., Vincent Chan, M.D., Michael Froeschl, M.D., C.M., Marino Labinaz, M.D., Michel R. Le May, M.D., Juan J. Russo, M.D., and Benjamin Hibbert, M.D., Ph.D.
doi : 10.1056/nejmoa2026845
N Engl J Med 2021; 385:516-525
Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the selection of inotropic agents in clinical practice.
Ivar M. Austevoll, M.D., Ph.D., Erland Hermansen, M.D., Ph.D., Morten W. Fagerland, Ph.D., Kjersti Storheim, P.T., Ph.D., Jens I. Brox, M.D., Ph.D., Tore Solberg, M.D., Ph.D., Frode Rekeland, M.D., Eric Franssen, M.D., Clemens Weber, M.D., Ph.D., Helena Brisby, M.D., Ph.D., Oliver Grundnes, M.D., Ph.D., Knut R.H. Algaard, M.D., Tordis B?ker, M.D., Hasan Banitalebi, M.D., Kari Indrekvam, M.D., Ph.D., and Christian Hellum, M.D., Ph.D. for the NORDSTEN-DS Investigators*
doi : 10.1056/nejmoa2100990
N Engl J Med 2021; 385:526-538
In patients with lumbar spinal stenosis and degenerative spondylolisthesis, it is uncertain whether decompression surgery alone is noninferior to decompression with instrumented fusion.
Rajendra S. Apte, M.D., Ph.D.
doi : 10.1056/nejmcp2102061
N Engl J Med 2021; 385:539-547
Stephanie S. Cabler, M.D., and David A. Rosen, M.D., Ph.D.
doi : 10.1056/nejmicm2035551
N Engl J Med 2021; 385:548
Colleen J. Beatty, M.D., and Erica R. Ghareeb, M.D.
doi : 10.1056/nejmicm2101571
N Engl J Med 2021; 385:e19
Thomas W. Fredrick, M.D., Manuel B. Braga Neto, M.D., Ph.D., Daniel O. Johnsrud, M.D., Michael Camilleri, M.D., and Victor G. Chedid, M.D.
doi : 10.1056/nejmcps2105278
N Engl J Med 2021; 385:549-554
Barry R. Bloom, Ph.D., Debra Malina, Ph.D., Genevra Pittman, M.A., Stephen Morrissey, Ph.D., and Eric J. Rubin, M.D., Ph.D.
doi : 10.1056/nejme2110145
N Engl J Med 2021; 385:556-557
Mathew S. Maurer, M.D.
doi : 10.1056/nejme2110557
N Engl J Med 2021; 385:558-559
Katherine R. Tuttle, M.D.
doi : 10.1056/nejme2109957
N Engl J Med 2021; 385:560-561
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/nejme2112855
N Engl J Med 2021; 385:e25
Lawrence Corey, M.D., Chris Beyrer, M.D., M.P.H., Myron S. Cohen, M.D., Nelson L. Michael, M.D., Ph.D., Trevor Bedford, Ph.D., and Morgane Rolland, Ph.D.
doi : 10.1056/nejmsb2104756
N Engl J Med 2021; 385:562-566
doi : 10.1056/nejmc2107725
N Engl J Med 2021; 385:567-569
doi : 10.1056/nejmc2107920
N Engl J Med 2021; 385:570-571
doi : 10.1056/nejmc2110093
N Engl J Med 2021; 385:571-572
doi : 10.1056/nejmc2109509
N Engl J Med 2021; 385:572-574
doi : 10.1056/nejmc2109676
N Engl J Med 2021; 385:574-575
doi : 10.1056/nejmc2109448
N Engl J Med 2021; 385:575-576
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟